Verici Dx PLC Clarava(TM) poster to be presented at ASN Kidney Week
02 November 2023 - 6:00PM
RNS Non-Regulatory
TIDMVRCI
Verici Dx PLC
02 November 2023
Verici Dx plc
("Verici Dx" or the "Company")
Clarava(TM) poster to be presented at ASN Kidney Week
International clinical validation study data to be presented at
the largest global gathering of kidney health professionals
Verici Dx plc (AIM: VRCI), a developer of advanced clinical
diagnostics for organ transplant, announces that it will present a
poster on the successful international clinical validation study
for Clarava(TM), the Company's pre-transplant blood-based
prognostic test for the risk of early acute kidney transplant
rejection, at the American Society of Nephrology's annual
conference, ASN Kidney Week, being held from 2-5 November 2023 in
Philadelphia, PA.
The poster, titled " Multi-Center International Study to
Validate a Pre-Transplant Blood-Based Next-Generation Sequencing
(NGS) Signature Predicting Risk of Acute Rejection After Kidney
Transplant" , will be presented from 10am-12pm on 2 November, in
the Exhibit Hall at location TH-PO115.
The poster will describe the design and positive results of
Clarava's(TM) successful validation study, as previously announced,
and is expected to help establish the product within the
international nephrology community ahead of commercial launch.
Clarava(TM) is the only pre-transplant test of its kind
currently available that can risk stratify patients based on their
likely immune response to a transplanted organ. This allows
clinicians to identify patients most likely to require increased
monitoring, including increasing or decreasing adjustments in the
type, dose, and duration of immunosuppressive agents. Existing
approaches to assess rejection risk are standardised and typically
based on the recipient's race, age, previous transplant history and
whether they have antibodies against common donor antigens. As
previously reported, the Clarava(TM) personalised risk assessment
is especially important for the expanding Deceased Donor transplant
population.
Sara Barrington, CEO of Verici Dx, said: "ASN Kidney Week is an
important platform for Verici Dx to raise awareness of its products
including Clarava(TM) , being the largest international gathering
attended by kidney health professionals and featuring the latest
advances in treatment, research and cutting edge technology in the
field of nephrology."
Enquiries:
Verici Dx www.v ericidx .com
Sara Barrington, CEO Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Tel: 020 7496 3000
Adviser & Broker)
Aubrey Powell / Sam Butcher / Jalini
Kalaravy
Walbrook PR Limited Tel: 020 7933 8780 or vericidx@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502 558 258
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of
leading-edge tests forming a kidney transplant platform for
personalised patient and organ response risk to assist clinicians
in medical management for improved patient outcomes. The underlying
technology is based upon artificial intelligence assisted
transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for
transplant prognosis of risk of injury, rejection and graft failure
from pre-transplant to late stage. The Company also has a mission
to accelerate the pace of innovation by research using the fully
characterised data from the underlying technology, including
through collaboration with medical device, biopharmaceutical and
data science partners.
The foundational research was driven by a deep understanding of
cell-mediated immunity and is enabled by access to expertly curated
collaborative studies in highly informative cohorts in kidney
transplant.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFSFESFEDSESF
(END) Dow Jones Newswires
November 02, 2023 03:00 ET (07:00 GMT)
Verici Dx (LSE:VRCI)
Historical Stock Chart
From Jan 2025 to Feb 2025
Verici Dx (LSE:VRCI)
Historical Stock Chart
From Feb 2024 to Feb 2025
